Preferred Label : Atezolizumab/Bevacizumab/Carboplatin/Paclitaxel Regimen;
NCIt synonyms : Atezolizumab/Bevacizumab/Carboplatin/Paclitaxel; ABCP Regimen; Tecentriq/Avastin/Carboplatin/Taxol; Atezolizumab-Bevacizumab-Carboplatin-Paclitaxel; Atezolizumab-Bevacizumab-Carboplatin-Paclitaxel Regimen;
NCIt related terms : ABCP; ABCP (bevacizumab-bvzr); ABCP (bevacizumab-adcd); ABCP (bevacizumab-equi); ABCP (bevacizumab-aybi); ABCP (bevacizumab-onbe); ABCP (bevacizumab-awwb); ABCP (bevacizumab-maly); ABCP (bevacizumab-tnjn); Carboplatin and Paclitaxel (CP), Atezolizumab, Bevacizumab; Carboplatin and Paclitaxel (CP), Atezolizumab, Bevacizumab-adcd; Carboplatin and Paclitaxel (CP), Atezolizumab, Bevacizumab-aybi; Carboplatin and Paclitaxel (CP), Atezolizumab, Bevacizumab-awwb; Carboplatin and Paclitaxel (CP), Atezolizumab, Bevacizumab-equi; Carboplatin and Paclitaxel (CP), Atezolizumab, Bevacizumab-onbe; Carboplatin and Paclitaxel (CP), Atezolizumab, Bevacizumab-maly; Carboplatin and Paclitaxel (CP), Atezolizumab, Bevacizumab-bvzr;
NCIt definition : A regimen consisting of atezolizumab, bevacizumab, carboplatin, and paclitaxel that
can be used in the treatment of cervical cancer and non-small cell lung cancer (NSCLC).;
NCI Metathesaurus CUI : CL936977;
Codes from synonyms : 29978; 127344; 127566; 127640; 127418; 127270; 127492; 127196; 59585; 139850; 141975; 139851; 139847; 139846; 139845; 139849; 139848;
Origin ID : C157394;
UMLS CUI : C4761554;
Automatic exact mappings (from CISMeF team)
- Semantic type(s)
- chemotherapy_regimen_has_component
- concept_is_in_subset
